Sun Sep 15 14:46:52 UTC 2024: ## Novo Nordisk Sees Increased Investor Interest Amid Strong Earnings Performance

**New York, NY (MarketBeat News)** – Novo Nordisk A/S (NYSE:NVO), the pharmaceutical giant known for its diabetes and obesity treatments, has seen a surge in investor interest in recent quarters. According to Holdings Channel.com, several hedge funds have either acquired new stakes or increased their existing positions in the company.

**Meeder Advisory Services** initiated a new stake in Novo Nordisk during the second quarter, acquiring 6,190 shares valued at approximately $884,000. **Aveo Capital Partners** also acquired a new stake during the fourth quarter, worth approximately $205,000. Other investors who increased their holdings include **9258 Wealth Management LLC**, **Rollins Financial**, and **Charles Schwab Investment Management Inc.**

Despite missing analysts’ expectations for its most recent quarterly earnings, Novo Nordisk reported strong revenue of $9.82 billion for the quarter, beating estimates for the quarter. The company also declared a semi-annual dividend of $0.5126, representing a yield of 0.7%.

Analysts remain bullish on Novo Nordisk’s future prospects. **Argus** recently upped its target price on the stock to $160.00, while **Cantor Fitzgerald** reiterated an “overweight” rating and issued a $160.00 price target. **The Goldman Sachs Group** also initiated coverage on the stock with a “buy” rating and a $156.00 price objective.

Based on data from MarketBeat.com, Novo Nordisk currently has an average rating of “Moderate Buy” and an average target price of $145.17.

These developments suggest that investors are optimistic about Novo Nordisk’s ability to maintain its strong financial performance and capitalize on the growing demand for its products in the diabetes and obesity markets.

Read More